ArticleStem cell research & therapy2026
HA-UCMSCs as an innovative therapy for treating multiple organ dysfunction syndrome.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMultiple organ dysfunction syndrome (MODS) is highly lethal and lacks effective therapies. Umbilical cord-derived mesenchymal stem cells (UCMSCs) regulate immunity, suppress inflammation, and promote tissue repair, suggesting potential benefit for MODS. However, despite over 1400 MSC-related clinical studies worldwide, inconsistent outcomes reflect the lack of potent, standardized products. Our group established highly active UCMSCs (HA-UCMSCs) with enhanced proliferative and reparative capacity. This study evaluated their efficacy in MODS and explored underlying mechanisms.
methodsMODS was induced in tree shrews by combining hemorrhagic shock, simulated infection, and hind limb compression. HA-UCMSCs were isolated, expanded, and characterized for their nuclear-to-cytoplasmic ratio, proliferation rate, multilineage differentiation capacity, and expression of mesenchymal and embryonic stem cell surface markers. After intravenous infusion, therapeutic efficacy was assessed via hematological and biochemical parameters, histopathological analysis, and serum proteomics using data-independent acquisition (DIA) mass spectrometry.
resultsHA-UCMSCs exhibited enhanced biological features compared to conventional UCMSCs, including high proliferative capacity and ESC marker expression. In vivo, HA-UCMSCs homed to injured organs, alleviated systemic inflammation, facilitated tissue regeneration, and maintained hematopoietic homeostasis. Treatment significantly reduced mortality and long-term disability in MODS. DIA proteomic analysis identified 18 candidate serum proteins associated with disease progression and treatment efficacy.
conclusionThis study introduces a clinically relevant tree shrew model of MODS and demonstrates the multi-organ protective effects of HA-UCMSCs. These findings highlight HA-UCMSCs as a promising stem cell-based therapy for MODS and propose novel serum biomarkers for treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.